What makes Stayble unique

Stayble Therapeutics is dedicated to developing an effective treatment option for lumbar disc herniation (LDH) using the company's drug candidate, STA363. This minimally invasive treatment offers an efficient and simple solution for the millions of individuals suffering from pain, where pain medication or physical therapy have proven ineffective.

Read more

Get to know Stayble

Latest press releases

January 31, 2025 Regulatorisk

(SV) – Stayble Therapeutics AB (publ) offentliggör utfallet av utnyttjande av teckningsoptioner av serie TO2

EJ FÖRPUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA,...

January 22, 2025

Abstract on the effect of STA363 on disc volume from the phase 1b study has been accepted for oral presentation at a major international congress

Stayble Therapeutics AB ("Stayble" or "the Company") announces that its scientific abstract on the effect of STA363 on disc volume reduction in patients with lumbar...

What makes stayble unique?

STA363 towards disc herniation place Stayble in a the forefront of injection-based, minimally invasive treatments for leg pain. As Stayble has developed successfully, the Company is competing to become the market leader in second-line therapies for pain caused by disc hernia.

About Stayble

TREATMENT OF LUMBAR DISC HERNIATION (LDH)

We are currently conducting a clinical phase 1b study in disc herniation. Read more about the study below.

LDH CANDIDATE

Invest in the future treatment of leg pain

Stayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.

Investors

Bridging the therapeutic gap

The majority of patients suffering from unresolved disc hernia are not helped by conservative treatment with analgesics and physiotherapy. With no long term treatment options than surgery most of these patient continues to suffer without improvment.

Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.

About Stayble